supporting ‘global best practice’

Throughout 2013/14, Snowdome was successful in joining several like-minded major donors* to establish the Centre of Research Excellence in Myeloma (CRE-M) in Melbourne. This $3million investment will support a global best practice research approach in ‘personalised or precision medicine’ which, according to reports from the U.S. and Canada, is an emerging approach for the treatment … Continued

A Researcher’s Insight – Azacitidine/Eltrombopag study

In a final analysis of the Peter Mac sponsored Azacitidine/Eltrombopag study, haematologist and research fellow, Dr Michael Dickinson, targets myelodysplastic syndromes and gives us a lay summary of the purpose of the trial.  Myelodysplastic syndromes are a group of conditions that lead to ineffective production of normal blood cells by the bone marrow. Patients present … Continued

a researcher’s insight – dr jake shortt

Dr Jake Shortt views haematology and blood cancers as one of the most complex aspects of medicine. He enjoys the intellectual challenge of researching blood cancers and likes to question established dogmas and ‘think outside of the square’. During Dr Shortt’s PhD project, he was using a solvent, N-methyl-2-pyrrolidone (NMP), to administer drugs to myeloma … Continued

‘making hope real’ for patients with MDS

In June this year at the European Haematology Association meeting in Italy, Dr Melita Kenealy, project manager of the Victorian Epigenetics Group, presented the first results of her recently led, large Australian study for patients with Myelodysplastic syndromes. Here is a brief summary of her report, “First Analysis ALLG MDS4 Study”:- ‘Making hope real’ for … Continued